Dr. Sanders is President and CEO of The Global Telemedicine Group, Professor of Medicine at Johns Hopkins University School of Medicine (Adjunct), and a founding board member of the American Telemedicine Association where he serves as President Emeritus...
Dr. Wilson is currently an Associate Professor of Surgery at Howard University College of Medicine. Dr. Wilson is the Division Chief of Surgical Oncology, which focuses on health disparities in underrepresented populations as well as breast, colorectal, and endocrine cancers...
Dr. Naeim is an Associate Professor of Medicine at the University of California Los Angeles with training and board certification in Internal Medicine, Medical Oncology, Geriatrics, and Clinical informatics. His research focus is in health services...
Dr. Kaufman has lectured across the country and published numerous articles and abstracts on the diagnosis and treatment of breast cancer. He has been involved with teaching physicians about breast cancer both nationally and internationally for over 20 years...
LOS ANGELES, CALIFORNIA – June 23rd , 2016 – Medical Tactile Inc. (MTI), the manufacturer of the SureTouch device, a breakthrough technology for Screening Clinical Breast Examinations, announced today that it is the recipient of the Medical Design Excellence Award in the Diagnostic Products category.
The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry that recognizes significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. Of the 100 candidates that applied this year in the Diagnostic Products category, seven finalists were selected to compete for three awards. An independent judging panel named MTI as one of those three award recipients at a ceremony on June 14 th , 2016 at the Javits Convention Center in New York.
“We are proud to be recognized for an award whose primary purpose is to honor companies that improve the quality of healthcare. The award is one more validation of our mission to deliver more accurate breast cancer screening with a technology that avoids delayed results, pain or exposure to radiation.” said Dr. Jae Son, Chairman of MTI.
“Our SureTouch technology is the foundation of an accurate early detection process that is inexpensive, highly portable and can operate in any location. By transforming access to and engagement of early breast cancer detection, SureTouch can lead a truly global advance in screening that will dramatically reduce the proportion of breast cancers diagnosed at later stages – still the best means of reducing the deaths from this terrible disease. SureTouch recognition by the MDEA is well deserved recognition of the truly transformational system our team has created." said Dr. Joe Peterson, CEO of MTI.
For more information, visit our website at www.suretouch.us or contact:
Joe Peterson, MD, CEO of Medical Tactile, Inc.
SureTouch Breast Exam is a painless, radiation free, Screening Clinical Breast Examination with immediate digital results. The SureTouch System is a cloud based medical device comprised of a wireless sensor, touch screen display, and SureTouch network and is enabled by proprietary tactile sensor technology to capture the sense of touch. The SureTouch breast exam is FDA-cleared (FDA #K010514) and provides a safe, ultra-sensitive and reliable screening clinical breast examination with immediate, objective, digitized results for patients and doctors. The sensitivity, accuracy and immediacy of the breast screening results provided by SureTouch enables patients and doctors to take potentially life-saving action in the event of an abnormality. SureTouch is an ideal Screening Clinical Breast Exam that empowers clinicians and healthcare providers to:
Efficiently provide superior patient care
Deliver and document a more accurate breast examination than a standard Clinical Breast Exam (CBE) therefore improving the detection rate of breast abnormalities
Utilize the cost-effective SureTouch technology to confirm the absence of cancer
About Medical Design Excellence Award
The Medical Design Excellence Awards competition is the medtech industry's premier awards program. It honors achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. Each year, a panel of jurors comprised of designers, engineers, and clinicians awards bronze, silver, gold, and best-in- show honors to the most innovative products on the market in nine categories.
SURETOUCH™, A PAIN-FREE, RADIATION-FREE DIGITAL BREAST EXAM, TO BE PRESENTED AT THE 2014 SAN ANTONIO BREAST CANCER SYMPOSIUM ON DECEMBER 10TH, 2014
SureTouch identifies breast cancer with comparable sensitivity and specificity as other standard imaging modalities, summary of studies in over 1,000 patients finds.
Los Angeles, CA (December 10, 2014) – Medical Tactile, Inc. (MTI), manufacturer of SureTouch, a digital tactile imaging screening device for breast cancer detection, today announced that a summary of published clinical studies using tactile imaging in more than 1,000 patients will be presented at the San Antonio Breast Cancer Symposium (SABCS) on December 10th, 2014. Cary Kaufman, M.D., past President of the National Consortium of Breast Centers and Associate Clinical Professor of Surgery at the University of Washington, led the team that reviewed clinical data demonstrating that Tactile Imaging (SureTouch) not only is more sensitive in detecting breast masses in symptomatic patients when compared with the manual clinical breast exams but also identifies breast cancer with similar sensitivity and specificity compared with standard imaging modalities such as mammography and ultrasound (see Table 1).
SureTouch is a FDA-cleared (FDA #K010514) device utilizing tactile imaging technology. Patients are examined with a transducer the size of a computer mouse which is passed over the breast reading any areas of increased hardness commonly associated with tumors. The SureTouch exam is conducted in the physician’s office in a short time and is reimbursed using existing CPT codes. Its ease of use and low equipment cost makes it accessible to address healthcare disparities. Tactile Imaging delivers immediate results without pain or radiation at lower cost than other standard breast imaging modalities. With SureTouch, the examiner can identify the size, shape, hardness and location of suspicious masses during the real-time examination. Many breast cancers, especially those that are more serious, can be identified with the sense of touch. As demonstrated in the summary of clinical studies to be presented at SABCS, Tactile Imaging (SureTouch) was more sensitive than clinical breast exam (human touch).
"SureTouch represents a significant expansion in our ability to perform a breast examination. It provides consistency, sensitivity, accuracy, and documentation that improve our abilities to examine the breast." said Dr. Kaufman. "The results of our presentation further validate the promising potential of Tactile Imaging (SureTouch) in the screening and diagnosis for breast cancer."
There were nine clinical studies reviewed involving 1,155 symptomatic patients using SureTouch in the U.S., China, and UK. All studies included in this meta-analysis were on symptomatic patients. In studies that examined the ability to identify the presence of a breast abnormality, the sensitivity of Tactile Imaging was 89% in comparison with clinical breast exam which was 83%. The studies that examined the identification of breast cancer using imaging modalities, the comparisons are summarized in Table 1.
Table 1. Breast Cancer Detection Summary on Symptomatic Patients
|Sensitivity for Cancer Detection||85||76||90|
|Specificity for Cancer Detection||79||71||79|
|Accuracy for Cancer Detection||82||74||84|
“Sure Touch was created to provide women with early awareness of any abnormalities and give peace of mind for the vast majority of women who are examined with no abnormalities during periodic wellness exams. SureTouch is beginning to achieve clinical acceptance at major medical centers and physician offices in the U.S. The impressive data presented at SABCS is another milestone in the SureTouch journey to become a vital examination for breast cancer screening,” said Dr. Jae Son, Chairman & Interim CEO of MTI.
About Medical Tactile
Medical Tactile, Inc. (“MTI”) is a Delaware Corporation that manufactures and markets SureTouch, a screening device for breast cancer detection using its proprietary tactile imaging technology. Its mission is to deliver more accurate breast cancer detection without pain or radiation at lower cost. SureTouch is a safe, painless, radiation-free digital breast exam. It is FDA-cleared (FDA #K010514) for producing surface map of the breast as an aid to document palpable breast lesions identified during a clinical breast exam. SureTouch utilizes tactile sensing technology, originally developed at Harvard University, to capture the sense of touch which has been used for cancer detection for thousands of years and accounts for 80% of breast cancers found today. Breasts are examined quickly and comfortably without compression or radiation. The patented, hand-held, SureTouch sensor glides easily over the entire breast and underarm area. Its 192 sensing elements capture and document the shape, location, size and hardness of breast lesions. Any breast lesions are displayed on SureTouch console screen as two- and three-dimensional full-color images. Because images are digitally stored for future reference, results can be tracked and compared for changes over time.
SureTouch Awarded Prestigious 2014 Patrick Soon-Shiong Innovation Award by the Los Angeles Business Journal
LOS ANGELES, CALIFORNIA – November 19th, 2014 – Medical Tactile Inc. (MTI), manufacturer of SureTouch, a screening device for breast cancer detection, today announced today that it is the recipient of the Los Angeles Business Journal's 2014 Patrick Soon-Shiong Innovation Award. The prestigious honor celebrates organizations that stretch boundaries and advance the innovative and economic competitiveness of the Los Angeles region.
Fifteen finalists were selected this year to compete for five awards. An independent judging panel named the 2014 recipients and the award was handed out to SureTouch at a ceremony on November 18th, 2014 at the Four Seasons Hotel Los Angeles in Beverly Hills.
“We are proud to be named among the innovative companies recognized for an award whose primary purpose is to honor companies that try to make the world a better place by thinking differently. The award marks another milestone in our long journey for making SureTouch the standard of care for breast cancer screening and fulfilling its mission to deliver more accurate breast cancer detection without pain or radiation at significantly lower cost.” said Dr. Jae Son, Chairman and Interim CEO of MTI.
Dr. Son Receives Patrick Soon-Shiong 2014 Innovation Award
SureTouch is a FDA-cleared device utilizing tactile imaging technology to detect breast cancer. The SureTouch Breast Exam is a simple procedure using a hand-held device that captures a graphic representation of an amplified map of breast tissue. With SureTouch, the patient and the doctor can view the size, shape, hardness and location of suspicious masses immediately during the examination and masses as small as 5mm can be identified, thus facilitating immediate and potentially life-saving actions. While 80 percent of newly diagnosed breast cancers are found by the sense of touch, SureTouch is far more sensitive than human touch and can detect smaller lesions than a trained clinician. Women love SureTouch because it is pain free, radiation free and provides immediate results. SureTouch is effective with younger women and older women even with fibrous breast tissue. Because SureTouch is safe, women are encouraged to get examined more frequently.
About The Patrick Soon-Shiong Innovation Awards
One of the wealthiest people in Los Angeles, and a past recipient of the LABJ's Business Person of the Year, Dr. Patrick Soon-Shiong's groundbreaking concepts for curing diabetes led to the first nanotechnology-based breast cancer drug, Abraxane, which is credited with saving thousands of lives. Now, for the fifth year, his love of innovation has prompted him to again join the Business Journal in handing out the Patrick Soon-Shiong Innovation Awards to deserving organizations.
For more information, contact:
Joe Peterson MD, CEO